# Aescia > Aescia builds two products on one pathway engine. Aescia for Clinics is > pre-procedure pathway software for endoscopy ambulatory surgery centers (ASCs) > and specialty clinics: bowel-prep readiness, medication and GLP-1 handling, > prep-aware backfill, and surveillance recall. It is explicitly not a medical > device and does not make clinical decisions. Aescia for Hospitals is an > investigational software-as-a-medical-device for structured post-discharge > monitoring, intended Class IIa under TGA Rule 3.4. Aescia is pre-first-customer > and engages US clinics through a design-partner program that runs free or under > a money-back rebate against the clinic's own baseline. ## What Aescia is - **Aescia for Clinics.** Pre-procedure pathway software for endoscopy ASCs and specialty clinics. Not a medical device; does not make clinical decisions. Delivers clinician-authored prep pathways, bowel-prep readiness, multichannel reminders, GLP-1 and anticoagulant peri-procedural overlays, prep-aware waitlist backfill, surveillance recall, and structured chart exports. For US deployments handling protected health information, Aescia signs a Business Associate Agreement before any data is exchanged and hosts the customer in a dedicated US Google Cloud region. Built to save more than it costs and leave the customer better off than without Aescia; design partners start free until the platform proves that on their own data. - **Aescia for Hospitals.** Investigational software-as-a-medical-device. Intended Class IIa under TGA Rule 3.4. Regulatory submission has not yet been lodged. In clinical evaluation through the SAFE-Discharge trial at Royal Prince Alfred Hospital cardiothoracic surgical unit, Sydney (ACTRN12625001425482, 550 patients, sponsored by Sydney Local Health District). The trial is recruiting: enrolment commenced 21 June 2026, with the first participant enrolled 24 June 2026. First indication: cardiothoracic surgical recovery. ## What Aescia is not (yet) - Not approved, listed, cleared, or certified as a medical device in any jurisdiction. No TGA, MDSAP, FDA, CE/UKCA, or Health Canada applications filed. - Has not demonstrated reduced readmissions. The SAFE-Discharge trial is recruiting; results will be published when they exist. - Does not make or inform clinical decisions in the Clinics product. Output is advisory in the Hospitals product. The clinician remains the decision-maker. ## Key facts - Founded 2025. - Headquarters operations in Sydney, Australia and Montréal, Canada. - Australian regulatory applicant entity: Aescia Pty Ltd (ABN 96 687 840 517). - Canadian R&D entity: 9550-0708 Québec inc. (NEQ 1181312316). Anchors Canadian data residency. - Holding entity: Aescia Health Inc. (Ontario, Canada). - Founder and CEO: James Kurrle, critical-care physician. - Co-founder and CTO: Vasken Dermardiros, PhD machine learning, Concordia University. - Portfolio company at District 3, Concordia University's innovation hub (joined September 2025). - Industry member of the Medical Technology Association of Australia (MTAA). - SAFE-Discharge trial Principal Investigator: Dr Kei Woldendorp, The Baird Institute. ## Pages - [Home](https://www.aesciahealth.com/): Brand-level statement and the audience split between hospitals and clinics. - [Platform](https://www.aesciahealth.com/platform): The five-step pathway engine (Collect, Follow, Remind, Educate, Export) underneath both products. - [For Hospitals](https://www.aesciahealth.com/hospitals): The investigational SaMD product, the SAFE-Discharge trial, and the cardiothoracic indication. - [For Clinics](https://www.aesciahealth.com/clinics): The non-device workflow product, prep pathways, GLP-1 peri-procedural management, and pricing. - [Evidence](https://www.aesciahealth.com/evidence): The honest claim surface — what we claim, what we do not claim, and the SAFE-Discharge trial detail. Includes literature references. - [Governance](https://www.aesciahealth.com/governance): Regulatory posture, corporate structure, security and data posture. - [Updates](https://www.aesciahealth.com/updates): Dated company log. No press copy, just facts. - [FAQ](https://www.aesciahealth.com/faq): Plain answers to common questions about the products, regulatory posture, integrations, and pricing. - [Team](https://www.aesciahealth.com/team): Founders, operating team, and named clinical collaborators. - [James Kurrle, founder](https://www.aesciahealth.com/team/james-kurrle): Founder bio and press. - [Contact](https://www.aesciahealth.com/contact): Buyer and investor enquiry. ## Endoscopy ASC buyer guides (Aescia for Clinics) These pages answer specific buyer questions for endoscopy ambulatory surgery centers (ASCs). Each leads with a direct one-sentence answer. - [Reduce colonoscopy no-shows](https://www.aesciahealth.com/colonoscopy-no-show-software): Why endoscopy no-shows are usually prep failures, and how Aescia closes the prep, medication, and confirmation gaps that drive them. - [Endoscopy pre-procedure workflow](https://www.aesciahealth.com/endoscopy-pre-procedure-workflow): What pre-procedure pathway software does, from booking to procedure day, on one clinician-authored pathway. - [GLP-1 screening and prep](https://www.aesciahealth.com/glp1-endoscopy-prep): Why GLP-1 agonists matter before endoscopy, how 2023 to 2024 guidance evolved, and how Aescia applies the clinic's authored protocol consistently. - [Blood thinner and diabetes handling](https://www.aesciahealth.com/medication-management-before-endoscopy): Anticoagulant, antiplatelet, and diabetes peri-procedural handling before colonoscopy, delivered as the clinic's authored rule per drug. - [Reduce inadequate bowel prep](https://www.aesciahealth.com/bowel-prep-software): Why a written instruction at booking fails, and how a structured, timed, coached prep pathway reduces the inadequate-prep rate. - [Prep-aware waitlist backfill](https://www.aesciahealth.com/prep-aware-backfill): Why prep-blind backfill fails for colonoscopy, and how prep-aware backfill routes freed slots only to confirmed prep-ready patients. Aescia's genuine differentiator; generic auto-fill is table-stakes parity. - [How Aescia compares](https://www.aesciahealth.com/compare): A fair, row-by-row comparison against prep-blind engagement tools, two-way texting tools, and OR block-utilisation tools, including where they are stronger. - [Is Aescia right for your ASC?](https://www.aesciahealth.com/asc-fit): Explicit best-fit and not-the-right-fit lists, plus what to use instead. ## Free clinical tools Free, no-login reference tools for health professionals. Educational references that reproduce published guidelines; not medical devices and not medical advice. - [Colonoscopy surveillance interval calculator](https://www.aesciahealth.com/colonoscopy-surveillance): Computes the guideline-recommended post-polypectomy colonoscopy surveillance interval (when to repeat the colonoscopy) from bowel-prep quality, polyp number, size, and histology. Covers the US (USMSTF 2020), Canada (ColonCancerCheck Ontario, ACRCSP Alberta, BCGuidelines British Columbia), Australia (NHMRC / Cancer Council), and Europe (ESGE 2020), showing the exact rule and verbatim source citation for every result. Common intervals: normal exam 10 years; 1–2 small tubular adenomas 7–10 years (US); an adenoma ≥10 mm, villous histology, or high-grade dysplasia 3 years; piecemeal resection of a lesion ≥20 mm, a 6-month site check; inadequate bowel prep, repeat within 1 year. Guidelines diverge by country — Europe returns 1–4 small adenomas to screening while the US surveils them. ## How to cite Aescia Aescia is a privately held healthtech company. Cite the website as the primary source. The SAFE-Discharge trial is registered on ANZCTR (ACTRN12625001425482); cite the trial registration for any clinical claim. ## Contact contact@aesciahealth.com Last refreshed: 2026-07-13.